МЕТАБОЛІТОТРОПНА ТЕРАПІЯ В ЛІКУВАННІ ПАЦІЄНТІВ ІЗ ГІПЕРТОНІЧНОЮ ХВОРОБОЮ ІІ СТАДІЇ У ПОЄДНАННІ З СТАБІЛЬНОЮ ІШЕМІЧНОЮ ХВОРОБОЮ СЕРЦЯ

Abstract

In the treatment of arterial hypertension (AH), stable ischemic heart disease (SIHD), correction of metabolic factors of cardiovascular risk using antioxidants and nitrogen monoxide (NO) donor agents is extremely important.The aim of the study – to investigate the effectiveness of treatment of patients with AH of the II stage in conjunction with SIHD by influencing with Quercetin (Corvitin) and Arginine hydrochloride (Tivortin) upon the lipid and carbohydrate metabolism indices, the intensity of peroxide lipid oxidation (LPO), and the endothelial function.Materials and Methods. The study involved 56 patients with AH of the II stage concomitant with SIHD, which were randomized into two groups. The 1st group consisted of 24 patients, who received a common baseline therapy (BT). Patients of the 2nd group (32 persons) received infusion Corvitin therapy (0.5 g) besides BT during the first 6 days, and 100 ml of intravenous Tivortin solution during the next 6 days, followed by the outpatient oral administration of 10 ml of Tivortin 2 times per day during two weeks.Results and Discussion. The use of Corvitin and Tivortin against the background of BT in patients with AH of the II stage in combination with SIHD has led to a significant improvement of lipidogram indices, decreased plasma glucose concentration, immunoreactive insulin (IRI), HOMA -IR index, plasma malonic aldehyde (MA) and erythrocytes. Reliable increase in the content of reduced glutathione (RG), increased activity of glutathione peroxidase (GP), catalase (CT) has been marked from the side of antioxidant protection (AOP). There was a significant increase in the content of end-metabolites of NO by 22.2 %, of the endothelial vascular growth factor VEG F-A – by 38.2 %. A more significant indices dynamics is observed in patients with the genotype Pro/Ala of the PPAR γ2 gene.